Strategies in the management of alemtuzumab-related side effects
B-cell chronic lymphocytic leukemia has traditionally been treated with alkylating agents and purine analogues. The introduction of alemtuzumab, a CD52 monoclonal antibody with significant clinical activity in chemotherapy refractory B-cell chronic lymphocytic leukemia, is accompanied by a side effe...
Saved in:
Published in | Seminars in oncology Vol. 33; no. 2 Suppl 5; p. S29 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.04.2006
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Be the first to leave a comment!